Proteinuria Treatment Market By Type | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Proteinuria Treatment Market
Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)
Report Code : HCR 0358
Updated Date: 16 August, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Proteinuria is a result of an excess of serum proteins in the urine, which can led to renal damage. The most common cause of proteinuria is diabetes. Globally, development the arena of proteomics and nanotechnology, rising incidences of chronic and autoimmune diseases, rise in the awareness among people regarding proteinuria treatment, increasing focus on research and development process, development in drug delivery system, and advantages of protein based drugs such as, high specificity, enhanced efficacy, affinity, solubility, and low incidences of toxicity are the prime growth drivers of proteinuria treatment market. In addition, increase in adoption of proteinuria treatment in emerging economies such as China, India and others, will create new opportunities for proteinuria treatment market. However, higher cost of the research and development, and complex government approval processes are the key restraints for proteinuria treatment market.

 Proteinuria Treatment Market

Geographically North America dominated proteinuria treatment market, with approximately half of the market in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing population chronic and autoimmune diseases patient in developing nations such as China, and India in this region. Among all the types, antibody segment has the highest market share in proteinuria treatment market due to higher prevalence of cancer patients.

This report identifies the global proteinuria treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global proteinuria treatment market.

This report segments proteinuria treatment market on the basis of type and regional market as follows:
  • Proteinuria Treatment Market, By Type: Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the proteinuria treatment market. Some of the major companies’ profiles in detail are as follows:
  • Eli Lilly
  • Abbott Laboratories
  • UCB Group
  • Schering-Plough Corporation
  • Genentech Inc.
1. Proteinuria Treatment Market – Market Overview
2. Executive Summary 
3. Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Proteinuria Treatment Market– Market Forces
   4.1. Drivers
      4.1.1. Development the arena of proteomics and nanotechnology
      4.1.2. Growing incidences of chronic and autoimmune diseases
   4.2. Restraints
      4.2.1. Higher cost of research and development  
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Proteinuria Treatment Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Proteinuria Treatment Market, By Type
   6.1. Angiotensin Converting Enzyme (ACE) Inhibitors
   6.2. Aldosterone Antagonist (i.e., spironolactone)
   6.3. Angiotensin Receptor Blocker (ARB)
   6.4. Others 
7. Proteinuria Treatment Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America 
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Proteinuria Treatment – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. Eli Lilly
   9.2. Abbott Laboratories
   9.3. UCB Group
   9.4. Schering-Plough Corporation
   9.5. Genentech Inc.
   9.6. Johnson & Johnson
   9.7. Bristol-Myers Squibb
   9.8. Novo Nordisk
   9.9. Biogen Idec
   9.10. Dendreon Corporation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports